Catalyst Dossier · compiled by CeliA 🧫
Genprex, Inc. (GNPX)
Pharmaceutical Preparations · market cap $7M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Genprex, Inc. (GNPX) is a small-cap clinical-stage pharmaceutical company with a market cap of approximately $85M and no revenue. Its sole disclosed pipeline asset, quaratusugene ozeplasmid, is in Phase 2 development for non-small cell lung cancer (NSCLC). The company holds $18M in cash, implying a runway of roughly 17 months.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| quaratusugene ozeplasmid | Phase 2 | Carcinoma, Non-Small Cell Lung |
Price & technical context
3-month
-68.1%
6-month
-80.8%
12-month
-95.8%
52-wk range
$0.64–$42.00
vs 50-day MA
-31.8%
vs 200-day MA
-84.8%
Realized vol
185.1%
Max drawdown
-99.6%
Daily closes through 2026-06-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GNPX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.